Stoke Therapeutics, Inc. Logo

Stoke Therapeutics, Inc.

Developing RNA-based medicines for genetic diseases by increasing protein from the healthy gene.

STOK | US

Overview

Corporate Details

ISIN(s):
US86150R1077
LEI:
Country:
United States of America
Address:
45 WIGGINS AVENUE, 1730 BEDFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines to treat severe genetic diseases. The company's proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), aims to restore normal protein levels by increasing—or "stoking"—protein expression from the healthy copy of a mutated gene. This approach is primarily designed to address haploinsufficiencies, where a single functional gene is insufficient to prevent disease. Stoke's lead candidate, zorevunersen (STK-001), is in clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company's pipeline also includes programs for other genetic disorders, such as autosomal dominant optic atrophy (ADOA).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Stoke Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Stoke Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Stoke Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM

Talk to a Data Expert

Have a question? We'll get back to you promptly.